Product Information
XMD16-5 is a pharmacologic drug that inhibits the activity of a number of tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR). XMD16-5 has been shown to be effective in leukemia cells. It has also been shown to inhibit the activity of BCR-ABL, an oncogenic tyrosine kinase. XMD16-5 is a multi-kinase inhibitor with targetable properties. It has been shown to have a high degree of selectivity for PDGFR and VEGFR over other kinases. This drug is being developed by Novartis as a targeted therapy for cancers with activating mutations in these two receptors.
Chemical properties
Technical inquiry about: 3D-VDC09878 XMD16-5
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
